Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injuryParticipants to include people ...

Kiniksa (KNSA) shifts from survival to growth as Arcalyst nears blockbuster sales and pipeline KPL-387 readouts loom—get the ...

Scotland has approved its first CLDN18.2-targeted therapy for advanced gastric and GEJ cancer, expanding options for patients ...

As deaths rose and treatments failed, morale among healthcare workers was at an all-time low. During that time, Dr. David Thrasher received a call from an Eli Lilly executive announcing emergency use ...

Immunocore is expanding its ImmTAX platform into autoimmune disease, outlining plans at the 44th Annual JP Morgan Healthcare ...

The National Institute for Health and Care Excellence has approved a breakthrough combination treatment for lupus nephritis, offering new hope to nearly 12,000 people in England living with the ...

In the treatment of inflammatory bowel disease, synthetic mucus gels can be used to deliver monoclonal antibodies without inducing broad immunosuppression.

NICE has recommended obinutuzumab with mycophenolate for severe lupus nephritis after trials showed higher renal response and fewer flares.

India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has approved a wide range of recombinant DNA (r-DNA)-origin drugs and biologics for manufacture ...

The single-dose injection can help prevent RSV. Learn how it works and when your baby may be eligible.

1. Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to phase II clinical research in idiopathic pulmonary fibrosis. News release. Boehringer-Ingelheim. January 13, 2026. Accessed ...

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 23 scientific posters at Maui Derm ...